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Background: In chronic lymphocytic leukemia (CLL), next-generation sequencing (NGS) analysis represents a sensitive,
reproducible, and resource-efficient technique for routine screening of gene mutations.
Methods: We performed an extensive biologic characterization of newly diagnosed CLL, including NGS analysis of 20
genes frequently mutated in CLL and karyotype analysis to assess whether NGS and karyotype results could be of clinical
relevance in the refinement of prognosis and assessment of risk of progression. The genomic DNA from peripheral blood
samples of 200 consecutive CLL patients was analyzed using Ion Torrent Personal Genome Machine, a NGS platform that
uses semiconductor sequencing technology. Karyotype analysis was performed using efficient mitogens.
Results: Mutations were detected in 42.0 % of cases with 42.8 % of mutated patients presenting 2 or more mutations.
The presence of mutations by NGS was associated with unmutated IGHV gene (p = 0.009), CD38 positivity (p = 0.010), risk
stratification by fluorescence in situ hybridization (FISH) (p< 0.001), and the complex karyotype (p = 0.003). A high risk as
assessed by FISH analysis was associated with mutations affecting TP53 (p = 0.012), BIRC3 (p = 0.003), and FBXW7
(p = 0.003) while the complex karyotype was significantly associated with TP53, ATM, and MYD88 mutations (p = 0.003,
0.018, and 0.001, respectively). By multivariate analysis, the multi-hit profile (≥2 mutations by NGS) was independently
associated with a shorter time to first treatment (p = 0.004) along with TP53 disruption (p= 0.040), IGHV unmutated status
(p < 0.001), and advanced stage (p< 0.001). Advanced stage (p = 0.010), TP53 disruption (p< 0.001), IGHV unmutated status
(p = 0.020), and the complex karyotype (p= 0.007) were independently associated with a shorter overall survival.
Conclusions: At diagnosis, an extensive biologic characterization including NGS and karyotype analyses using novel
mitogens may offer new perspectives for a better refinement of risk stratification that could be of help in the clinical
management of CLL patients.
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Chronic lymphocytic leukemia (CLL) displays a heteroge-
neous clinical course [1–3], some patients living for years
with asymptomatic disease and others experiencing early
progression requiring therapeutic intervention. Modern
treatment algorithms must take into account age, comor-
bidities, and prognostic/predictive factors, including
genetic lesions [4]. Adverse prognostic factors include
stage [5], positivity for CD38, ZAP70, and CD49d [6–8],
and, among genetic features, the unmutated configuration
of the variable region of the immunoglobulin heavy chain
gene (IGHV) [6] and specific molecular cytogenetic lesions
revealed by fluorescent in situ hybridization (FISH). More
recently, karyotype aberrations were shown to represent
strong prognostic factors [9–14], and large retrospective
studies demonstrated that TP53, NOTCH1, and SF3B1
gene mutations have a negative impact on the time to
first treatment (TTFT) and overall survival (OS) [15–17].
These data were in part confirmed by prospective clinical
trials using homogeneous treatment protocols [18, 19],
and recurrent genomic lesions were included within com-
prehensive prognostic indexes [20, 21] helping clinicians
to counsel patients more appropriately, to define the
follow-up interval, and, potentially, to provide a rational
basis to design early intervention protocols for high-risk
patients [22].
Next-generation sequencing (NGS) techniques docu-
mented that, besides the aforementioned genes, a num-
ber of previously unidentified genes may be mutated in
CLL and that the disruption of putative core cellular
pathways represents an important mechanism promot-
ing disease progression and drug resistance [23–26].
NGS may detect minor cell populations (subclones) har-
boring a variety of gene mutations, including NOTCH1,
SF3B1, BIRC3, and TP53 mutations, the latter having a
negative prognostic impact that was similar to TP53
clonal mutations [27–29] as detected by conventional se-
quencing techniques (i.e., Sanger sequencing).
Thus, NGS is becoming of age for usage in clinical
practice, and indeed, over 50 % of CLL patients were
shown to carry mutations in one or more genes [30, 31],
potentially making NGS a sensitive tool for the detection
of mutations including subclonal mutations.
To assess whether an extended mutational screening by
NGS at diagnosis could allow for a refinement of our cap-
ability to predict TTFT and OS, we designed a CLL-
specific gene panel, covering hotspots or complete coding
regions of 20 genes more frequently mutated in CLL. We
performed NGS of these 20 genes using a resource-
efficient platform in 200 consecutive newly diagnosed pa-
tients representing over 90 % of CLL incident cases in our
region. By correlating mutational data obtained by an ex-
tensive genetic/cytogenetic characterization with clinic-
biological parameters and outcome, we were able to showthat NGS screening was an independent prognostic factor
for TTFT and that complex karyotype was a strong pre-
dictor of an inferior survival in this patient population.
Methods
Patients
The study cohort consisted of 200 consecutive un-
treated CLL patients diagnosed and followed between
2007 and 2014. All patients were diagnosed according
to NCI criteria [32]. Only patients with a Matutes
immunophenotypic score [33] ≥3 (i.e., typical CLL)
were included. CD38 and ZAP-70 were tested on per-
ipheral blood (PB) cells, as described [34]. When
needed, mantle cell lymphoma was excluded by the
evaluation of cyclin D1. The study was approved by the
local ethics committee. Indications for treatment included
increased white blood cell count with <6 month lympho-
cyte doubling time, anemia or thrombocytopenia due to
bone marrow infiltration or autoimmune phenomena not
responding to steroids, and disease progression in the
Binet staging system. Fludarabine and bendamustine
(since 2010), containing regimens in association with or
without rituximab, were used as first-line treatment; chlor-
ambucil was used in elderly and unfit patients according
to shared treatment policy adopted at our center.
Cytogenetic and FISH analyses
Interphase FISH was performed on PB samples obtained
at diagnosis using probes for the following regions: 13q14,
12q13, 11q22/ATM, and 17p13/TP53 (Vysis/Abbott Co,
Downers Grove, IL) as described [35]. Each patient was
categorized into a FISH risk group according to the fol-
lowing classification: favorable group (isolated 13q14 de-
letion or absence of FISH aberrations), unfavorable group
(deletions of 11q22 or of 17p13), and intermediate group
(trisomy 12).
Cytogenetic analysis was performed on the same sam-
ples used for FISH analysis using CpG-oligonucleotide
DSP30 (2 μmol/l TibMolBiol Berlin, Germany) plus IL2
(100 U/ml Stem Cell Technologies Inc., Milan, Italy) as
described [36]. The complex karyotype was defined by
the presence of at least 3 chromosome aberrations.
IGHV analysis
IGHV genes were amplified from genomic DNA and se-
quenced according to standard methods with the cutoff
of 98 % homology to the germline sequence to discrim-
inate between mutated (<98 %) and unmutated (≥98 %)
cases, as reported [35].
Ion Torrent Personal Genome Machine (PGM) analysis
NGS analysis was performed on the same samples used
for FISH and cytogenetic analyses. In all samples, the
percentage of CLL cells was over 90 % as assessed by
Table 1 Clinical and biological characteristics of the 200 CLL
patients
Variable
Age, median yrs (range) 67.6 (38.3–89.9)
Sex m/f 121/79




13q14 deletion yes/no 104/96
Trisomy 12 yes/no 32/168
11q22 deletion yes/no 20/180
17p13 deletion yes/no 9/191
FISH fav/int/unfav 142/30/28
Complex karyotype no/yes 167/28
Mutated patients by NGS no/yes 116/84
No. of mutations by NGS 0/1/2/3/4 116/48/24/8/4
TP53 mut/WT 16/184
TP53 disruption yes/no 19/181
f female, fav favorable, int intermediate, m male, mut mutated, neg negative,
pos positive, unfav unfavorable, unmut unmutated, yrs years, TP53 disruption
17p13 deletion and/or TP53 mutation
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ment kit (Agilent Technologies, Santa Clara, CA, USA)
was used to produce libraries of exonic regions from 20
genes (ATM, BIRC3, BRAF, CDKN2A, PTEN, CDH2,
DDX3X, FBXW7, KIT, KLHL6, KRAS, MYD88, NOTCH1,
NRAS, PIK3CA, POT1, SF3B1, TP53, XPO1, ZMYM3)
starting from genomic DNA from PB samples, according
to HaloPlex Target Enrichment System (Agilent Tech-
nologies, Santa Clara, CA, USA). Diluted libraries were
linked to Ion Sphere Particles, clonally amplified in an
emulsion PCR and enriched using Ion OneTouch emul-
sion PCR System (Life technologies, Foster City, CA,
USA). Exon-enriched DNA was precipitated with mag-
netic beads coated with streptavidin. Enriched, template-
positive Ion Sphere Particles were loaded in one ion chip
and sequenced using Ion Torrent PGM (Life technologies,
Foster City, CA, USA). Sequencing data were aligned to
the human reference genome (GRCh37). Data analysis
and variant identification were performed using Torrent
Suite 3.4 and Variant Caller plugin 3.4.4 (Life technologies,
Foster City, CA, USA) [37].
Statistical analysis
The Mann-Whitney and the Pearson’s chi-squared tests
were applied for quantitative and categorical variables,
respectively. TTFT was calculated as the interval be-
tween diagnosis and the start of first-line treatment. OS
was calculated from the date of diagnosis until death
due to any cause or until the last patient follow-up.
Survival curves were compared by the log-rank test.
Proportional hazards regression analysis was used to
identify the significant independent prognostic variables
on TTFT. The stability of the Cox model was internally
validated using bootstrapping procedures [15]. Statis-
tical analysis was performed using Stata 14.0 (Stata
Corp, College Station, TX).
Results
Patients and mutation analyses of the 20 genes by NGS
The clinical and biologic characteristics of the 200 CLL
patients are presented in Table 1.
Parallel sequencing of exonic regions from the 20
genes showed somatic mutations in 84/200 (42.0 %)
cases. One hundred thirty-six mutations were found in
these 84 patients; 114 missense mutations, 7 nonsense
mutations, 14 frameshit deletions, and 1 frameshit inser-
tion. Mutations were detected with a frequency ranging
from 5.0 to 96.7 % of the reads. Sixteen cases (8.0 %)
showed mutations in the TP53 gene, 16 (8.0 %) in the
NOTCH1 gene, 15 (7.5 %) in the SF3B1 gene, 10 (5.0 %)
in the ATM gene, 8 (4.0 %) in the BIRC3 gene, 7 (3.5 %)
in the MYD88 gene, 7 (3.5 %) in the PTEN gene, 6
(3.0 %) in the FBXW7 gene, 5 (2.5 %) in the POT1 gene,
5 (2.5 %) in the BRAF gene, 5 (2.5 %) in the ZMYM3gene, and 19 (9.5 %) cases in the remaining 9 genes
(Additional file 1: Table S1). 36/84 (42.8 %) mutated pa-
tients presented 2 or more mutations (Additional file 2:
Table S2). TP53 mutations (p = 0.027) were significantly
more frequent among patients with 2 or more muta-
tions while a trend was observed for BIRC3 mutations
(p = 0.059) and mutations of genes less frequently mu-
tated in CLL (p = 0.057) (Additional file 3: Table S3).
Correlations between mutational status by NGS,
molecular cytogenetic findings, and clinico-biological
parameters
The presence of somatic mutations did not correlate
with sex, age, and Binet stage while the occurrence of
mutations by NGS analysis was significantly associated
with CD38 positivity (p = 0.010), IGHV unmutated sta-
tus (p = 0.009), intermediate high-risk cytogenetics by
FISH analysis (p < 0.001), and the complex karyotype
(p = 0.003; Table 2).
A higher risk as assessed by FISH analysis was asso-
ciated with the presence of mutations affecting TP53
(p = 0.012), BIRC3 (p = 0.003), and FBXW7 (p = 0.003)
while the complex karyotype was significantly associated
with TP53, ATM, andMYD88 mutations (p = 0.003, 0.018,
and 0.001, respectively: Table 3; Fig. 1).
The median follow-up for the 200 CLL patients was
52.3 months. In univariate analysis (Table 4), the occur-
rence of mutations and the presence of 2 or more
Table 2 Correlations between mutational status by NGS analysis






Sex m/f 49/35 72/44 0.594
Age <70/≥70 years 46/38 69/47 0.505
Binet stage a/b/c 66/12/6 95/13/8 0.802
CD38 neg/pos 42/42 79/37 0.010
IGHV mut/unmut 36/48 69/43 0.009
FISH fav/int unfav 48/36 94/22 <0.001
Complex karyotype no/yes 63/19 104/9 0.003
f female, fav favorable, int intermediate, m male, mut mutated, neg negative,
pos positive, unfav unfavorable, unmut unmutated, yrs years, TP53 disruption
17p13 deletion and/or TP53 mutation
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TTFT (Fig. 2) along with advanced Binet stage; CD38
positivity; IGHV unmutated status; intermediate un-
favorable FISH results; 11q22 deletion, 17p13 deletion,
and/or TP53 mutations (here referred to as TP53 dis-
ruption); and complex karyotype. A shorter TTFT was
also observed for TP53-, NOTCH1-, ATM-, and BRAF-
mutated patients. By multivariate analysis (Table 5), we
found that the multi-hit profile (≥2 mutations by NGS)
predicted a shorter TTFT (p = 0.004) along with TP53
disruption (p = 0.040), IGHV unmutated status (p <
0.001), and advanced stage (p < 0.001).
When considering OS (Table 4), a poorer prognosis
was associated with the occurrence of mutations by
NGS analysis, the presence of 2 or more mutations,
with TP53 mutations, and with advanced stage, CD38Table 3 Correlations between mutations by NGS analysis, FISH resul
FISH results
Fav Int-unfav
No. of mutations by NGS no/1/≥2 94/28/20 22/19/17
TP53 WT/mut 135/7 49/9
NOTCH1 WT/mut 133/9 51/7
SF3B1 WT/mut 132/10 53/5
ATM WT/mut 137/5 53/5
BIRC3 WT/mut 140/2 52/6
MYD88 WT/mut 136/6 57/1
PTEN WT/mut 138/4 55/3
FBXW7 WT/mut 141/1 53/5
POT1 WT/mut 138/4 57/1
BRAF WT/mut 139/3 56/2
ZMYM3 WT/mut 138/4 57/1
Others WT/mut 129/13 49/6
f female, fav favorable, int intermediate, m male, mut mutated, neg negative, pos popositivity, IGHV unmutated status, TP53 disruption,
and complex karyotype. In multivariate analysis, ad-
vanced stage (p = 0.010), IGHV unmutated status (p =
0.020), TP53 disruption (p < 0.001), and the complex
karyotype (p = 0.007) independently predicted a worse
outcome (Table 5).Discussion
CLL is the most frequent leukemia in western countries
and has a significant socioeconomic impact. It is there-
fore important to define which patients are at higher risk
of progression and therefore require stricter follow-up
and which genetic lesions are associated with risk of re-
lapse and/or chemorefractoriness ultimately determining
a shorter survival [22]. Unlike previous reports analyzing
prognostic/predictive factors in CLL requiring treatment
at the time of progression, we were able to perform an
extensive biologic characterization in an unselected pro-
spective series of 200 patients diagnosed over an 8-year
span and followed for a median of 52.3 months over the
last 10 years. Our center has a >90 % capture of each
incident case of CLL in our region of approximately
400,000 inhabitants because the diagnosis of CLL in our
province was centralized since 2006. With the exception
of frail patients with a significant number of comorbidi-
ties precluding any form of specific treatment, whom
were not submitted to extensive molecular cytogenetic
characterization, the patient population included in this
analysis is highly representative of the true nature of
CLL and allows meaningful analyses of TTFT and OS in
a real-world scenario.ts, and karyotype complexity
Complex karyotype
No Yes p
0.001 104/36/27 9/11/8 0.011
0.012 158/9 22/6 0.003
0.175 155/12 25/3 0.517
0.701 156/11 25/3 0.434
0.133 161/6 24/4 0.018
0.003 161/6 26/2 0.381
0.382 164/3 24/4 0.001
0.411 161/6 27/1 0.996
0.003 161/6 28/0 0.308
0.653 162/5 28/0 0.354
0.583 163/4 28/0 0.408
0.653 163/4 27/1 0.716
0.192 149/18 24/4 0.587
sitive, unfav unfavorable, unmut unmutated
Fig. 1 Gene mutations and correlation with genomic features: circos diagrams illustrating pairwise co-occurrence of gene mutations with IGHV
status, FISH results, and complex karyotype
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semiconductor sequencing technology. In clinical practice,
PGM may represent a very sensitive tool for mutational
screening of patients with CLL, allowing multiplexing of
samples and gene targets in one experimental setup [30]
and resulting in higher speed of analysis and lower costs
[38]. Parallel sequencing of exonic regions in these 20
CLL-related genes showed somatic mutations in 84/200
(42.0 %) cases by using a 5 % cutoff. Mutations weredetected with a frequency ranging from 5.0 to 96.7 % of
the reads, clearly showing that both major and minor
clonal mutations were present, the former representing
early leukemogenetic events and the latter representing
late-appearing aberrations possibly associated with disease
progression or chemorefractoriness [39, 40].
In this series, the frequency of mutations involving
TP53, NOTCH1, SF3B1, ATM, and BIRC3 genes clearly
reflects the nature of our patient cohort that included
Table 4 Univariate analysis for TTFT and OS
TTFT OS
Variable N pts HR (CI 95 %) p HR (CI 95 %) p
Binet stage B–C vs A 39 vs 161 9.884 (5.939–16.450) <0.0001 3.174 (1.677–6.007) 0.0002
CD38 pos vs neg 79 vs 121 4.097 (2.564–6.546) <0.0001 3.123 (1.686–5.783) 0.0001
IGVH mut vs unmut 105 vs 91 5.584 (3.326–9.374) <0.0001 3.667 (1.886–7.127) <0.0001
11q22 deletion yes vs no 20 vs 180 2.879 (1.528–5.426) 0.0006 1.736 (0.739–4.078) 0.2000
TP53 disruption yes/no 19 vs 181 3.284 (1.867–5.781) <0.0001 4.246 (2.076–8.687) <0.0001
FISH int-unfav vs fav 58 vs 142 2.605 (1.670–4.063) <0.0001 2.432 (1.438–4.454) 0.0029
Complex karyotype yes vs no 28 vs 167 2.979 (1.756–5.056) <0.0001 3.854 (1.961–7.578) <0.0001
Mutations by NGS no/yes 116 vs 84 2.835 (1.799–4.469) <0.0001 2.171 (1.176–4.008) 0.0130
Number of mutations by NGS
0 116 1 <0.001 1 0.037
1 47 2.373 (1.369–4.112) 0.002a 1.936 (0.930–4.032) 0.078a
≥2 37 3.418 (2.009–5.759) <0.001a 2.466 (1.187–5.126) 0.016a
TP53 mut vs wt 16 vs 184 2.804 (1.514–5.194) 0.0010 2.793 (1.284–6.098) 0.0069
NOTCH1 mut vs wt 16 vs 184 2.353 (1.164–4.762) 0.0141 2.646 (1.114–6.259) 0.0219
SF3B1 mut vs wt 15 vs 185 1.779 (0.886–3.571) 0.1006 1.170 (0.419–3.268) 0.7648
ATM mut vs wt 10 vs 190 3.623 (1.715–7.633) 0.0003 1.946 (0.686–5.525) 0.2023
BIRC3 mut vs wt 8 vs 192 0.817 (0.254–2.597) 0.7246 1.099 (0.252–4.808) 0.8998
MYD88 mut vs WT 7 vs 193 1.758 (0.642–4.812) 0.2724 1.505 (0.363–6.240) 0.5733
PTEN mut vs WT 7 vs 193 1.573 (0.574–4.310) 0.3780 1.503 (0.363–6.224) 0.5742
FBXW7 mut vs WT 6 vs 194 1.820 (0.664–4.988) 0.2441 1.445 (0.349–5.986) 0.6134
POT1 mut vs WT 5 vs 195 1.059 (0.259–0.321) 0.9375 0.978 (0.352–4.768) 0.9973
BRAF mut vs WT 5 vs 195 7.730 (3.014–19.827) <0.0001 2.126 (0.286–15.823) 0.4610
ZMYM3 mut vs WT 5 vs 195 0.484 (0.067–3.480) 0.4710 2.336 (0.563–9.693) 0.2434
OTHERS mut vs wt 19 vs 181 1.036 (0.517–2.075) 0.9205 0.898 (0.320–2.518) 0.8381
aCompared with no mutation
f female, fav favorable, int intermediate, m male, mut mutated, neg negative, pos positive, unfav unfavorable, unmut unmutated, yrs years, TP53 disruption 17p13
deletion and/or TP53 mutation
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of the disease and comprising 80.5 % of Binet stage A
cases. Approximately, the same incidence for these mu-
tations was reported in a series of CLL patients observed
in the general practice and not enrolled in clinical trials
[17]. The frequency of mutations involving the other in-
vestigated genes was in line with data published in litera-
ture using whole exome sequencing [41–44].
Interestingly, we observed that 18.0 % of the cases pre-
sented more than one mutation. In the CLL11 trial, 161
patients were evaluated at the time of treatment require-
ment and NGS analysis revealed mutations in 42 out of
85 analyzed genes, with 76.4 and 42.2 % of the patients
presenting at least one or ≥2 genes affected by muta-
tions, respectively [14].
In our series of patients, the occurrence of mutations
was associated with adverse molecular and genetic find-
ings including IGVH unmutated status, intermediate
high-risk FISH results, and the presence of a complexkaryotype. Noteworthy, a higher incidence of concurrent
mutations was observed in TP53-mutated patients, while
the presence of a complex karyotype was associated with
TP53-, ATM-, and MYD88-mutated cases. These results
suggest that concurrent mutations, as well as complex
karyotype, might represent an aspect of genetic instabil-
ity correlated to a defective DNA damage response [45].
We then analyzed the correlation between the muta-
tional status and outcome. A shorter TTFT was observed
in those patients with mutations by NGS and with muta-
tions involving TP53, NOTCH1, ATM, and BRAF. The
prognostic significance of BRAF mutations needs to be
confirmed on larger series because it was derived from a
limited number of patients, most of whom had concurrent
mutations of other genes. By multivariate analysis, we
found that the multi-hit profile (≥2 mutations by NGS)
was independently associated with a shorter TTFT along
with TP53 disruption, IGHV unmutated status, and ad-
vanced stage.
Fig. 2 TTFT according to number of mutations by NGS analysis (p < 0.001)
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gest that not only the presence of clones or subclones [46]
but also the concurrent presence of mutations may play a
significant role in prognostication. This study, to our
knowledge, provides the first demonstration that at diag-
nosis, in an unselected CLL patient population followed
up at one center having a >90 % capture of incident cases,
a multi-hit profile derived from an extensive NGS analysis
is independently associated with a shorter TTFT. Note-
worthy, concurrent gene mutations are also frequent in
patients with relapsed/refractory CLL and are associated
with a worse outcome [47].
When considering OS, a poorer outcome was associated
with the presence of mutations by NGS, with mutations in
TP53 and NOTCH1 genes, with the multi-hit profile, withTable 5 Multivariate analysis for TTFT and OS
TTFT
After bo
Variable HR CI p CI
Binet stage b–c vs a 11.206 6.384–19.671 <0.001 5.570–22
CD38 pos vs neg 1.141 0.670–1.942 0.627 0.663–1.
11q deletion yes vs no 1.306 0.619–2.755 0.484 0.532–3.
TP53 disruption yes vs no 2.255 1.168–4.352 0.015 1.039–4.
IGHV unmut vs mut 5.078 2.599–9.554 <0.001 2.491–10
No. of mutations by NGS
0 1 1
1 1.452 0.812–2.594 0.208 0.574–3.
≥2 2.791 1.468–5.306 0.002 1.375–5.
Complex karyotype yes vs no 1.649 0.896–3.034 0.108 0.824–3.
f female, fav favorable, int intermediate, m male, mut mutated, neg negative, pos po
deletion and/or TP53 mutationIGHV unmutated status, with TP53 disruption, and with
the complex karyotype. However, by multivariate analysis,
only TP53 disruption was independently associated with a
worse outcome along with advanced stage, IGHV unmu-
tated status, and the complex karyotype.
Whereas the strong independent impact on TTFT and
OS of IGHV mutational status and TP53 disruption was
previously demonstrated [12, 14, 15, 45, 46], the finding of
an independent impact on OS of the complex karyotype is
noteworthy, especially when considering that an extensive
clinic-biologic characterization was performed in this pa-
tient cohort. Recently, an independent prognostic rele-
vance on OS of the complex karyotype has emerged in
CLL patients investigated at different phases of the dis-
ease: at diagnosis [13, 34], before first-line treatment [14],OS
otstrapping After bootstrapping
p HR CI p CI p
.545 <0.001 3.080 1.501–6.319 0.002 1.302–7.286 0.010
938 0.634 1.067 0.506–2.249 0.864 0.448–2.356 0.883
205 0.560 Na Na Na Na Na
891 0.040 4.055 1.844–7.917 <0.001 1.897–8.670 <0.001
.354 <0.001 3.198 1.524–6.13 0.002 1.200–8.522 0.020
1 1
673 0.431 0.930 0.417–2.074 0.860 0.348–2.484 0.885
665 0.004 1.115 0.492–2.523 0.795 0.480–2.589 0.801
301 0.158 3.173 1.521–6.619 0.002 1.369–7.355 0.007
sitive, unfav unfavorable, unmut unmutated, yrs years, TP53 disruption 17p13
Rigolin et al. Journal of Hematology & Oncology  (2016) 9:88 Page 8 of 9and in refractory relapsed patients treated with ibrutinib
[48]. We may assume that the complex karyotype prob-
ably reflects a high level of genomic instability that ap-
pears to be a better predictor of worse OS in comparison
to single and multiple concurrent mutations, with the only
exception of TP53 mutations. Thus, karyotyping seems to
substantially contribute to the identification of CLL pa-
tients with most adverse prognosis and should be consid-
ered in an extensive diagnostic work-up in future CLL
trials [49, 50].Conclusions
Altogether, our data suggests that NGS may play an im-
portant role in the definition of the risk of disease pro-
gression and therefore could be useful in the diagnostic
work-up of CLL patients as an efficient, sensitive, and af-
fordable technique for routine screening of mutations.
Indeed, NGS analysis, in combination with clinical stage,
TP53 disruption, and IGHV assessment, may identify
those patients that are at higher risk of progression and
therefore need a stricter follow-up whereas karyotyping
could represent along with TP53 disruption the best
genetic predictor of OS. However, some issues need to
be better defined before the introduction of the ex-
tensive NGS approach into the routine clinical practice:
(i) which genes and how many genes should be included
in the work-up panel for an efficient and affordable rou-
tine applicability, (ii) what cutoff for mutational analysis
should be considered clinically relevant, and (iii) how to
develop a standardized methodology ensuring reproduci-
bility of the results [51].
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